Skip to main content
. Author manuscript; available in PMC: 2013 Sep 21.
Published in final edited form as: Biochem Biophys Res Commun. 2012 Aug 22;426(2):237–241. doi: 10.1016/j.bbrc.2012.08.073

Figure 1. Incidence of ventricular arrhythmia and recovery of action potentials during reperfusion in guinea-pig hearts.

Figure 1

The incidence of ventricular tachycardia (VT), ventricular fibrillation (VF) and recovery of action potential duration at 90% (APD90) at 20 min reperfusion are shown for untreated control, εPKC agonist ψεRACK (0.5 μM) and εPKC antagonist εV1 (0.5 μM) hearts. Hearts treated with εPKC agonist ψεRACK had the lowest incidence of VT/VF and complete recovery of APD90 compared with hearts treated with εPKC antagonist εV1 and control.